<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05627518</url>
  </required_header>
  <id_info>
    <org_study_id>CX842A2106</org_study_id>
    <nct_id>NCT05627518</nct_id>
  </id_info>
  <brief_title>Relative Bioavailability of Linaprazan for the Test Formulation vs. Reference Formulation</brief_title>
  <acronym>BA</acronym>
  <official_title>A Randomized, Single Dose, Crossover Study in Healthy Volunteers to Investigate the Relative Bioavailability of Linaprazan for a New Oral Tablet Formulation of Linaprazan Glurate, and to Assess the Effect of Food on the Pharmacokinetics of Linaprazan</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cinclus Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cinclus Pharma AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-center, open-label, randomized, single dose, 3-way crossover study in&#xD;
      healthy volunteers designed to evaluate the relative bioavailability of a new oral tablet&#xD;
      formulation of linaprazan glurate in comparison to a previously studied oral tablet&#xD;
      formulation under fasting conditions, and to assess the effect of a high fat, high calorie&#xD;
      meal on the pharmacokinetics (PK) of linaprazan glurate and the active substance linaprazan&#xD;
      after the administration of the new oral tablet formulation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 15, 2022</start_date>
  <completion_date type="Actual">January 2, 2023</completion_date>
  <primary_completion_date type="Actual">December 30, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measurement of pharmacokinetic profile of linprazan glurate and linaprazan (AUCinf)</measure>
    <time_frame>pre dose, 0,25h, 0,5h, 1h, 1,25h, 1,5h, 2h, 3h, 4h, 6h, 8h, 12h, 14h, 20h, 24h, 36h, 48h and 72 h post dose</time_frame>
    <description>Area under the plasma concentration vs. time curve (AUC) from time 0 to infinity (AUCinf)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measurement of pharmacokinetic profile of linprazan glurate and linaprazan (AUClast)</measure>
    <time_frame>pre dose, 0,25h, 0,5h, 1h, 1,25h, 1,5h, 2h, 3h, 4h, 6h, 8h, 12h, 14h, 20h, 24h, 36h, 48h and 72 h post dose</time_frame>
    <description>AUC from time 0 to the last measurable concentration (AUClast)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measurement of pharmacokinetic profile of linprazan glurate and linaprazan (Cmax)</measure>
    <time_frame>pre dose, 0,25h, 0,5h, 1h, 1,25h, 1,5h, 2h, 3h, 4h, 6h, 8h, 12h, 14h, 20h, 24h, 36h, 48h and 72 h post dose</time_frame>
    <description>Maximum plasma concentration (Cmax)</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Safety</condition>
  <condition>Bioavailability</condition>
  <condition>Pharmacokinetics</condition>
  <arm_group>
    <arm_group_label>Reference formulation (Treatment A)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>100 mg linaprazan glurate reference formulation, fasting conditions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Test formulation (Treatment B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 mg linaprazan glurate reference formulation, fasting conditions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Test Formulation (Treatment C)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 mg linaprazan glurate test formulation, fed conditions</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Linaprazan glurate</intervention_name>
    <description>100 mg</description>
    <arm_group_label>Reference formulation (Treatment A)</arm_group_label>
    <arm_group_label>Test Formulation (Treatment C)</arm_group_label>
    <arm_group_label>Test formulation (Treatment B)</arm_group_label>
    <other_name>formerly X842</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:&#xD;
&#xD;
          1. Willing and able to give written informed consent for participation in the study.&#xD;
&#xD;
          2. Healthy male or female aged 18 to 65 years, inclusive.&#xD;
&#xD;
          3. Body mass index ≥18.5 and ≤30.0 kg/m2.&#xD;
&#xD;
          4. Medically healthy, without abnormal clinically significant medical history&#xD;
&#xD;
          5. Female subjects of childbearing potential, as well as their partners and male subjects&#xD;
             and their partners, who agree to using methods of contraception&#xD;
&#xD;
          6. Willing and able to consume the high-fat, high calorie breakfast&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Female subjects of childbearing potential unless they agree to use highly effective&#xD;
             methods of contraception (failure rate of &lt;1%) from 2 weeks prior to dosing until the&#xD;
             end-of-study visit.&#xD;
&#xD;
          2. Male subjects with a partner of childbearing potential, unless they agree to use&#xD;
             method of contraception from 2 weeks prior to dosing until the end-of-study&#xD;
             visit.History of or current clinically significant disease as defined in the protocol&#xD;
&#xD;
          3. History of or current clinically significant disease as defined in the protocol.&#xD;
&#xD;
          4. History of GERD, significant acid reflux.&#xD;
&#xD;
          5. Subjects who are pregnant, currently breastfeeding, or intend to become pregnant&#xD;
             (female subjects) or father a child (male subjects) during the course of the study&#xD;
             (i.e., from screening to end of study visit).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tanja Turk, M. Pharm</last_name>
    <role>Study Director</role>
    <affiliation>CRS d.o.o.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CRS d.o.o.</name>
      <address>
        <city>Ljubljana</city>
        <state>Ukmarjeva Ulica 6</state>
        <zip>1000</zip>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Slovenia</country>
  </location_countries>
  <verification_date>January 2023</verification_date>
  <study_first_submitted>November 16, 2022</study_first_submitted>
  <study_first_submitted_qc>November 16, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 25, 2022</study_first_posted>
  <last_update_submitted>January 17, 2023</last_update_submitted>
  <last_update_submitted_qc>January 17, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

